November 16, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2604058

Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.

Listen to this summary

This phase 3, double-blind, placebo-controlled trial asked whether once-weekly semaglutide could safely and effectively reduce body-mass index in children aged 6 to under 12 years with obesity, a group with few durable medical treatment options. Among 167 children randomized 2:1 to semaglutide or placebo alongside lifestyle counseling, semaglutide produced a mean BMI reduction of 13.5% versus a 2.7% increase with placebo at week 68 (between-group difference -16.2 percentage points). Gastrointestinal adverse events were more common with semaglutide, but led to discontinuation in only one participant in that group.

Ania M Jastreboff, Nina M Harder-Lauridsen, Michelle Van Name, Antje Körner, Aaron S Kelly, Daniel Weghuber, Jens-Christian Holm, Christine Frithioff-Bøjsøe, Shilpa Middolu, Tina Buch, Martin Wabitsch

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play